Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2025 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicio
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to The Report
Biotech

Sana Biotechnology

Sana Biotechnology Raises $300M PIPE

$300M PIPE
Total Raised
2018
Founded
300-500
Employees
Seattle, WA
Updated October 23, 2025
2 min read

Quick Facts

Valuation
$1.8B

Sana Biotechnology Raises $300M PIPE

Cell engineering company developing ex vivo and in vivo cell therapies for diabetes, cancer, and genetic diseases

Key Highlights

  • Funding Amount: $300M PIPE
  • Valuation: $1.8B
  • Headquarters: Seattle, WA
  • Founded: 2018
  • Employees: 300-500
  • Total Raised: $700M

About the Funding Round

Sana Biotechnology has successfully closed $300M PIPE in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • Flagship Pioneering
  • Baillie Gifford
  • T. Rowe Price

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Sana Biotechnology achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Sana Biotechnology's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2018 and headquartered in Seattle, WA, Sana Biotechnology has established itself as an innovative player in the biotech space. With 300-500 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Sana Biotechnology plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Sana Biotechnology's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Sana Biotechnology, visit their website or contact their press office.

Key Investors

Flagship Pioneering
Strategic Investor
Life sciences venture creation firm
Baillie Gifford
Strategic Investor
Scottish investment management firm
T. Rowe Price
Strategic Investor
Global investment management firm

Topics

Venture Capital(911)BiotechFunding RoundGrowth RoundWA

About the Author

David Chen
David Chen
Technology investment researcher specializing in enterprise software and infrastructure deals at top-tier venture funds.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M